Pancrelipase is an oral gastrointestinal agent. It is derived from porcine pancreatic enzymes and contains lipase, amylase, and protease, which are capable of digesting fats, starches, and proteins, respectively. Pancrelipase has 12 times the lipolytic activity, 4 times the proteolytic activity, and 4 times the amylolytic activity of pancreatin. Pancreatic enzyme replacement is usually reserved for patients with chronic pancreatic exocrine insufficiency; the enzymes help to re-establish the natural digestive conditions in the intestine and control steatorrhea. Pancreatic insufficiency products are not clinically interchangeable and are not considered bioequivalent by the FDA.
In April 2004, the US Food and Drug Administration (FDA) notified manufacturers of pancreatic insufficiency products that these drugs must get FDA approval, via the submission of a new drug application (NDA), within the next 4 years in order to remain on the US market. The FDA notice covers pancreatic extract preparations containing pancreatin and pancrelipase. Both ingredients are extracted mainly from animal pancreata and contain principally amylase, protease, and lipase. The action followed an April 1995 decision that manufacturers of over-the-counter (OTC) pancreatic extract products must have FDA approval before marketing and that the FDA would approve pancreatic extract products as prescription-only (Rx-only) medicines. The FDA decided to require NDAs for these drug products after reviewing data that showed substantial variations in the formulation, dosage, and manufacturing processes of currently available products, variations which affect the potency of the enzymes and could significantly affect safety and effectiveness in the clinical treatment of patients. The FDA has stated that these variations in the potency of pancreatic extract drug product are unacceptable. Pancreatic extract products have a long history of use, some preceding the Federal Food, Drug, and Cosmetic Act of 1938. In April 2009, Creon (pancrelipase delayed-release capsules) became the first FDA approved pancreatic enzyme product in the US. Efficacy was demonstrated in a clinical study that included 32 patients with cystic fibrosis. Pancrelipase-treated patients had a mean CFA (percentage of fat absorption relative to dietary fat intake) of 89%, while patients who received placebo had a mean of 49%; a statistically significant difference. There were no relevant differences in magnitude of response between the two represented age groups (12 to 18 years and more than 18 years of age). The non-FDA approved pancrelipase products will continue to be available until the filing deadline date because of their established use as replacement therapy to treat serious conditions associated with pancreatic insufficiency, including chronic pancreatitis and cystic fibrosis (CF). Additional pancrelipase formulations have been approved. Zenpep was approved in August 2009 and Pancreaze was approved in April 2010. In 2012, Ultresa, Pertzye, Viokace products were FDA approved. Viokace, in combination with a proton pump inhibitor, is used to treat adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
General Administration Information
For storage information, see the specific product information within the How Supplied section.
NOTE: Pancreatic insufficiency products are not clinically interchangeable and are not considered bioequivalent by the FDA. Patients stabilized on one product should remain on that product unless the prescriber orders a specific change.
Route-Specific Administration
Oral Administration
-Follow oral dosage with a glass of water or juice (or formula or breast milk for infants). Administer with meals and snacks or just prior to meals and snacks. Do not retain preparations in the mouth prior to swallowing because the enzyme may cause mucosal irritation and stomatitis.
Oral Solid Formulations
Delayed-release capsules
-Administer during meals or snacks with sufficient fluid.
-Do not chew or crush; avoid destruction of enteric coating. The enteric coating will dissolve if in prolonged contact with foods having a pH greater than 5.5. If the enteric coating is destroyed, the enzymes present in pancrelipase may cause ulcerations.
-For patients unable to swallow intact capsules, products containing enteric-coated spheres, microspheres, or microtablets may be opened and the contents sprinkled on a soft acidic food (pH of 4 or 4.5 or less depending on the specific product). Choose a food that does not require chewing (e.g., commercially available preparations of bananas, pears, and applesauce). The soft food mixture should be swallowed immediately and followed with water or juice to ensure complete ingestion.
-Do not mix directly with infant formula or breast-milk; however, in infants, doses should be followed with a feeding of formula or breast milk.
Tablets
-Administer during meals or snacks with sufficient fluid.
-Should be swallowed whole. Do not chew or crush.
-Tablets that are not enteric-coated should be taken with a proton pump inhibitor.
Other Administration Route(s)
Administration via Gastrostomy Tube
-Administration of pancrelipase products via a gastrostomy tube presents a complex challenge; the risk of clogging the feeding tube must be balanced with the risk of reducing enzyme effectiveness.
-Consider the feeding tube size, feeding schedule (continuous or intermittent), pancrease product (specifically the size of the microspheres/granules), and other concurrent medications (i.e., medications that suppress gastric acid production) when determining the most appropriate method of administration for a specific patient.
Pertzye 4,000 USP lipase unit capsules (14 Fr gastrostomy tube or larger; no more than 2 capsules may be administered at a time)
-Transfer at least 10 mL of applesauce into a small bowl or medicine cup.
-Mix the capsule contents thoroughly with the transferred applesauce to create a uniform suspension. Do not crush the enzyme microspheres. Use immediately.
-Remove the plunger from a 35 mL slip tip syringe. While covering the tip of the syringe with a finger, transfer the Pertzye-applesauce mixture into the syringe. Replace the plunger partially back into the syringe.
-Shake or tap the syringe lightly with the syringe tip facing upward and carefully push the plunger slowly until the residual air is removed.
-Connect the syringe directly into the gastrostomy tube feeding port and push the syringe contents using steady pressure until empty.
-Flush the gastrostomy tube with approximately 10 mL of water. Discard any unused portion of the mixture.
-If dose requires more than 2 capsules, repeat the above steps until the desired dose is achieved.
Delayed-release capsules
-Two main methods of administration have been described: 1.) opening the capsules and mixing the contents with a thickened acidic liquid or thin food (e.g., baby food) and 2.) opening the capsule and dissolving the contents in sodium bicarbonate. These methods have different risks and advantages that must be considered on an individual patient basis.
-Mixing with thickened liquid (risk: tube occlusion; benefit: maintaining integrity of enteric coating which may preserve efficacy)-Using a mildly thickened liquid as the vehicle is thought to reduce the risk of tube occlusion compared to using water or other thin liquid because a thin liquid allows the enteric-coated microspheres/beads to settle and clump together in the feeding tube.
-Adequate flushing of the feeding tube before and after administration is critical. If direct contact occurs between the acidic fruit juice and enteral feedings inside the tube, an interaction can occur that may clog the feeding tube.
-Some dietary experts have proposed the following technique, which can be used for tube sizes 10 Fr and above. However, if sizes 10 Fr or 12 Fr are in place, the use of low-dose enzyme capsules (3,000 to 5,000 units of lipase) are recommended because they contain the smallest sized microspheres/beads.-Prepare 50 to 100 mL of mildly thickened fruit juice using a thickening agent (e.g., Nectar Thick).
-Open the pancrease capsule(s) into a small clean container.
-Add sufficient mildly thickened liquid to completely coat the microspheres/beads and stir gently to evenly suspend them in the liquid.
-If the patient is receiving continuous feedings, stop the tube feeds.
-Flush the feeding tube with an appropriate amount of water.
-Draw up the mixture with an enteral syringe of appropriate size for the volume and feeding tube size. Administer the mixture slowly through the feeding tube with slow, gentle pressure.
-Flush the feeding tube with water, and resume feeds.
-Mixing with baby food/applesauce (risk: tube occlusion; benefit: maintaining integrity of enteric coating which may preserve efficacy)-In an in vitro study, Creon capsules were opened and the contents sprinkled onto approximately 15 mL of baby food (applesauce or bananas with a pH less than 4.5) per capsule. The mixture was stirred gently and allowed to sit for 15 minutes. The mixture was then administered slowly through various gastrostomy tubes at a rate of about 15 mL per 10 to 15 seconds using a 35 mL syringe. The tube was then flushed with 10 to 30 mL of water.
-Pancrelipase doses were successfully administered through the following G-tubes: Kimberly-Clark MIC Bolus size 18 Fr or larger, Kimberly-Clark MIC-KEY 16 Fr or larger, Bard Tri-Funnel 18 Fr or larger, and Bard Button 18 Fr or larger. The tubes that were sizes smaller than those indicated as having successful administration became clogged with at least one of the baby foods tested. Administration was successful if there was no clogging of the tube and no visible pellet damage.
-Mixing with sodium bicarbonate solution (risk: reduced efficacy because enteric coat is removed; benefit: lower risk of tube occlusion)-When pancreatic enzyme products are administered into a feeding tube that is placed duodenally or jejunally, some experts recommend opening the capsules, crushing the enteric coated beads, and then mixing with sodium bicarbonate. For each 10,000 units of lipase, 10 mL of 8.4% sodium bicarbonate is recommended. Alternatively, the uncrushed bead/microspheres can be mixed with the sodium bicarbonate and allowed to dissolve (about 20 to 30 minutes). Administer the solution slowly through the feeding tube, and flush the tube with water before and after each dose.
-Although there is debate about using this method of administration for feeding tubes placed in the stomach because of the risk for enzyme inactivation, some centers use this method to avoid feeding tube occlusion. Monitor efficacy carefully.
Adverse effects associated with pancrelipase at recommended doses are generally negligible, assuming appropriate doses are used. Among patients receiving delayed-release pancrelipase capsules, the most common reported adverse reactions were gastrointestinal in nature, including: abdominal pain (3% to 18%), upper abdominal pain (5%), abnormal feces (1% to 4%), diarrhea (10%), dyspepsia (10%), flatulence (3% to 9%), and vomiting (6%). During clinical evaluation, gastrointestinal complaints were typically reported more often with placebo than with pancrelipase. Duodenitis and gastritis of moderate severity was reported by one patient 16 days after completing therapy with delayed-release pancrelipase capsules. Delayed- and immediate-release pancreatic enzyme products of different formulations have also been associated with diarrhea, constipation, and nausea. In addition, preparations that are retained in the mouth before swallowing can cause mucosal oral ulceration and stomatitis. Retention of the dosage form in the esophagus could cause esophagitis. In addition, pancrelipase tablets have been associated with reports of ascites (3%) and pruritus ani (7%).
A syndrome of bowel fibrosis known as fibrosing colonopathy (submucosal fibrosis on histiologic examination) has been reported in association with pancreatic enzyme use. This rare adverse reaction has been observed in patients taking pancreatic enzymes for prolonged periods and is most commonly reported among pediatric patients with cystic fibrosis. In addition, colonic strictures have been reported in children less than 12 years of age receiving pancreatic enzyme doses greater than 6000 lipase units/kg/meal. Due to an increased risk of stricture formation, patients presenting with fibrosing colonopathy should be closely monitored. The underlying mechanism of fibrosing colonopathy is unknown and once present regression is uncertain. The long-term safety profile of delayed-and immediate-release pancreatic enzyme products has been described in the medical literature. Along with fibrosing colonopathy, the most serious adverse events include distal intestinal obstruction syndrome (GI obstruction) and recurrence of pre-existing carcinoma.
Relatively common adverse events reported among patients receiving pancrelipase independent of formulation, include: contusion (4% to 6%), cough (4% to 10%), dizziness (4% to 6%), ear pain (otalgia, 11%), early satiety (6%), epistaxis (7%), headache (3% to 15%), hyperglycemia (2%), hypoglycemia (2%), infection (3% to 11%), lymphadenopathy (11%), nasal congestion (14%), naso-pharyngitis (4%), neck pain (14%), and pharyngolaryngeal pain (7%). In addition, pancrelipase tablets have been associated with reports of anemia (3%), cholelithiasis (7%), hydro-cholecystitis (3%), peripheral edema (3%), and renal cyst (3%).
During postmarketing experience, blurred vision, myalgia, and muscle cramps have been reported with at least one formulation. During postmarketing experience, asymptomatic elevated hepatic enzymes have been reported with the Creon brand delayed-release capsules.
Large doses have been associated with hyperuricemia and hyperuricosuria. Porcine-derived pancreatic enzyme products contain purines that may increase blood uric acid levels. Caution is warranted when prescribing pancrelipase to patients with gout, renal impairment, or hyperuricemia.
Rarely, severe allergic reactions including anaphylactoid reactions, asthma (bronchospasm), hives, pruritus, rash (unspecified), and urticaria have been reported with pancreatic enzyme products. Pancrelipase causes skin rash (maculopapular rash) in a small percentage of patients. This appears to be part of a porcine hypersensitivity reaction to the pork protein in pancrelipase.
Certain tablet preparations of pancrelipase contain lactose. Administration of pancrelipase tablets may cause lactose intolerance symptoms such as nausea/vomiting, bloating, abdominal pain (cramps), and flatulence. Use appropriate precautions when administering to patients with lactose intolerance (lactase deficiency).
Pancrelipase is produced from porcine pancreatic enzyme concentrate; therefore, it should be used with caution in patients with porcine protein hypersensitivity. Discontinue pancrelipase if hypersensitivity occurs during treatment. Rarely, severe allergic reactions including anaphylaxis, asthma, hives, and pruritus, have been reported with some pancreatic enzyme products.
Pancrelipase is sourced from the pancreatic tissue of swine used for food consumption. In order to minimize the risk of viral transmission to humans, certain steps (including testing for and inactivating known viruses) are taken throughout the manufacturing process of pancrelipase. There is, however, a theoretical risk for transmission of a viral infection caused by a novel or unidentified virus. Although there have not been any reported cases of viral transmission associated with the use of porcine pancreatic extracts, the presence of porcine viruses that might infect humans cannot be definitely excluded.
Pancrelipase delayed release capsules are enteric-coated to resist inactivation by gastric acid, and to release most of the enzymes in the duodenum at a pH greater than 5.5. Therefore, delayed release capsules should not be crushed or chewed or mixed in foods having a pH greater than 4. If the protective coating is disrupted irritation of oral mucosa, and/or loss or enzyme activity can occur. For patients with dysphagia, specifically difficulty swallowing capsules, the capsules may be carefully opened and the contents added to a small amount of acidic soft food with a pH of < 4 or 4.5 depending on the specific product, such as applesauce, at room temperature (see Administration). Care should be taken when administering pancrelipase to patients with esophageal stricture or abnormalities to prevent the retention of the dosage within the esophagus and subsequent mucosal irritation.
Porcine-derived pancreatic enzyme products contain purines that may increase blood uric acid levels. Caution should be exercised when prescribing pancrelipase to patients with gout, renal impairment, or hyperuricemia.
Fibrosing colonopathy is a rare, serious adverse effect associated with high doses of pancreatic enzyme replacement therapy (PERT). It was initially described in patients taking high doses of pancreatic enzymes for prolonged periods of time, and it is most commonly reported among pediatric patients with cystic fibrosis. In its most advanced form, fibrosing colonopathy leads to colonic stricture. Consider fibrosing colonopathy in patients who have evidence of GI obstruction, bloody diarrhea, or chylous ascites and in patients who have a combination of abdominal pain with continuing diarrhea, poor weight gain, or both. Patients at highest risk include those who are < 12 years old, have taken > 6000 lipase units/kg/meal for more than 6 months, have a history of meconium ileus or distal intestinal obstruction syndrome, have had any intestinal surgery, or have a diagnosis of inflammatory bowel disease. The underlying mechanism of fibrosing colonopathy is unknown and once present regression is uncertain. Should signs or symptoms of GI obstruction occur, the possibility of GI strictures should be considered, and pancrelipase therapy should be reevaluated.The Cystic Fibrosis Foundation Consensus Conferences Guidelines has set forth dosing recommendations that should not be exceeded. If a patient's dose of pancreatic enzyme exceeds 2,500 lipase units/kg/meal (or greater than 10,000 lipase units/kg/day), further investigation is necessary. Response to enzyme treatment varies among patients, therefore if steatorrhea persists, the dosage may be increased by a healthcare professional; patients must not increase their own dose. Furthermore, the efficacy of doses greater than 2,500 lipase units/kg/meal (or greater than 10,000 lipase units/kg/day) must be confirmed by a 3-day fecal fat measure indicating a significantly improved coefficient of fat absorption. An adjustment period of several days may be required for dosage changes.
Published data from case reports with pancrelipase use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Pancrelipase has minimal systemic absorption, so maternal use is not expected to result in fetal exposure to the drug. Animal reproduction studies have not been conducted with pancrelipase.
Use pancrelipase with caution during breast-feeding; patients should notify their healthcare professional if they are intending to breast-feed. The risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a nursing mother with exocrine pancreatic insufficiency. Pancreatic enzymes act locally in the gastrointestinal tract and are unlikely to be systemically absorbed; however, some of the constituent amino acids and proteins in the pancrelipase product may be absorbed systemically along with normal dietary proteins. It is not known if pancrelipase or these constituents is distributed into breast milk. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
In patients with diabetes mellitus or at risk for abnormal blood glucose levels, glycemic control may be affected by administration of pancrelipase. Consideration should be given to additional glucose monitoring in these patients.
Pancrelipase products are NOT interchangeable. In some cases, the substitution of one product for another has resulted in therapeutic failures and adverse events. Dosage must be individualized according to patient need and response.
For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions:
NOTE: These pancrelipase products are not interchangeable.
-for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis:
Oral dosage (delayed-release capsules; Creon, Zenpep):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day.
Children and Adolescents 4 to 17 years: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Children 1 to 3 years: 1,000 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Infants: 3,000 lipase units PO per 120 mL of formula or breast milk. Do not mix capsule contents directly into formula or breast milk.
Neonates: 3,000 lipase units PO per 120 mL of formula or breast milk. Do not mix capsule contents directly into formula or breast milk.
Oral dosage (delayed-release capsules; Pancreaze):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day.
Children and Adolescents 4 to 17 years: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Children 1 to 3 years: 1,000 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Infants: 2,600 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Neonates: 2,600 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Oral dosage (delayed-release capsules; Pertyze):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day.
Children and Adolescents 4 to 17 years: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Children 1 to 3 years: 1,000 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Infants: 4,000 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Neonates: 4,000 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
-for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy:
Oral dosage (delayed-release capsules; Creon, Zenpep):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day. Doses of 72,000 lipase units/meal have been studied in adults age 32 to 75 years with pancreatic insufficiency due to chronic pancreatitis; these patients were consuming at least 100 g of fat/day.
Children and Adolescents 4 to 17 years: 500 to 1,000 lipase units/kg/meal, or alternately, 500 lipase units/g fat ingested/day, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 3,000 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. The FDA-approved dosage is 500 lipase units/kg/meal PO, initially. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Children 1 to 3 years: 500 to 1,000 lipase units/kg/meal, or alternately, 500 lipase units/g fat ingested/day, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 3,000 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. The FDA-approved dosage is 1,000 lipase units/kg/meal PO, initially. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/gram fat ingested/day.
Infants: 3,000 lipase units PO per 120 mL of formula or breast milk. Do not mix capsule contents directly into formula or breast milk.
Neonates: 3,000 lipase units PO per 120 mL of formula or breast milk. Do not mix capsule contents directly into formula or breast milk.
Oral dosage (delayed-release capsules; Pancreaze):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day.
Children and Adolescent 4 to 17 years: 500 to 1,000 lipase units/kg/meal, or alternately, 500 lipase units/g fat ingested/day, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 3,000 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. The FDA-approved dosage is 500 lipase units/kg/meal PO, initially. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Children 1 to 3 years: 500 to 1,000 lipase units/kg/meal, or alternately, 500 lipase units/g fat ingested/day, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 3,000 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. The FDA-approved dosage is 1,000 lipase units/kg/meal PO, initially. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/gram fat ingested/day.
Infants: 2,600 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Neonates: 2,600 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Oral dosage (delayed-release capsules; Pertyze):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day.
Children and Adolescent 4 to 17 years: 500 to 1,000 lipase units/kg/meal, or alternately, 500 lipase units/g fat ingested/day, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 3,000 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. The FDA-approved dosage is 500 lipase units/kg/meal PO, initially. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day.
Children 1 to 3 years: 500 to 1,000 lipase units/kg/meal, or alternately, 500 lipase units/g fat ingested/day, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 3,000 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. The FDA-approved dosage is 1,000 lipase units/kg/meal PO, initially. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/gram fat ingested/day.
Infants: 4,000 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Neonates: 4,000 lipase units PO per 120 mL of formula or breast milk. Do not mix directly in formula or breast milk.
Oral dosage (tablets; Viokace 10 or Viokace 20):
Adults: 500 lipase units/kg/meal PO, initially. Adjust dose based on clinical symptoms, steatorrhea, and fat content of diet. Generally, use one-half the mealtime dose with each snack. Max: 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day or 4,000 lipase units/g fat ingested/day. Older patients may require a decreased dosage expressed as lipase units/kg/meal, as they weigh more but tend to ingest less fat/kg/day. Doses of 125,280 lipase units/meal have been studied in adults age 24 to 70 years with pancreatic insufficiency due to chronic pancreatitis or pancreatectomy; these patients were consuming at least 100 g of fat/day. Due to lack of enteric coating, administer in combination with a proton pump inhibitor.
For enteral feeding tube occlusion*:
Enteral administration dosage (Viokace tablets):
Adults: 1 Viokace tablet (strength not specified) and one 325-mg sodium bicarbonate tablet crushed and dissolved in 5 mL of warm water. If a clogged Dobbhoff feeding tube (8 Fr) was not able to be cleared using water, then the pancreatic enzyme/sodium bicarbonate solution was instilled into the clogged tube and clamped for 5 minutes. Then, a 50-mL syringe was attached to the feeding tube using an adapter, and the tube was gently flushed with tap water. This procedure was effective in 72% (23 of 32) of the cases, and the authors state that the clearance rate is even higher if the cause of the obstruction is clotted enteral formula and the pancreatic enzyme solution is applied close to clotted formula using a small catheter. The reported data used a formulation of Viokace tablets that is no longer commercially available. The appropriateness of extrapolating to currently available tablet formulations is unknown.
Adolescents: In a case series that included some adolescents, 1 Viokace tablet (strength not specified) and one 325-mg sodium bicarbonate tablet were crushed and dissolved in 5 mL of warm water. If a clogged Dobbhoff feeding tube (8 Fr) was not able to be cleared using water, then the pancreatic enzyme/sodium bicarbonate solution was instilled into the clogged tube and clamped for 5 minutes. Then, a 50-mL syringe was attached to the feeding tube using an adapter, and the tube was gently flushed with tap water. This procedure was effective in 72% (23 of 32) of the cases, and the authors state that the clearance rate is even higher if the cause of the obstruction is clotted enteral formula and the pancreatic enzyme solution is applied close to clotted formula using a small catheter. The reported data used a formulation of Viokace tablets that is no longer commercially available. The appropriateness of extrapolating to currently available tablet formulations is unknown.
Maximum Dosage Limits:
-Adults
Maximum dosage information is product-specific; individualize dosage. The Cystic Fibrosis Foundation recommends a maximum dose of 10,000 lipase units per kg per day PO or less than 4,000 lipase units per gram dietary fat per day.
-Geriatric
Maximum dosage information is product-specific; individualize dosage. The Cystic Fibrosis Foundation recommends a maximum dose of 10,000 lipase units per kg per day PO or less than 4,000 lipase units per gram dietary fat per day.
-Adolescents
10,000 lipase units/kg/day or 4,000 lipase units/gram fat ingested/day. Dosages usually don't exceed 2,500 lipase units/kg/meal, but 3,000 lipase units/kg/meal has been recommended for chronic pancreatitis.
-Children
10,000 lipase units/kg/day or 4,000 lipase units/gram fat ingested/day. Dosages usually don't exceed 2,500 lipase units/kg/meal, but 3,000 lipase units/kg/meal has been recommended for chronic pancreatitis.
-Infants
2,600 lipase units per 120 mL formula or per breast-feeding for Pancreaze; 3,000 lipase units per 120 mL formula or per breast-feeding for Creon and Zenpep; 4,000 lipase units per 120 mL formula or per breast-feeding for Pertzye; do not exceed 4,000 lipase units per gram of ingested fat per day or 10,000 lipase units/kg per day. Safety and efficacy not established for brands not listed.
-Neonates
Maximum dosage information is product-specific; 2,600 lipase units per 120 mL formula or per breast-feeding for Pancreaze; 3,000 lipase units per 120 mL formula or per breast-feeding for Creon and Zenpep; 4,000 lipase units per 120 mL formula or per breast-feeding for Pertzye; safety and efficacy not established for other brands.
Patients with Hepatic Impairment Dosing
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Patients with Renal Impairment Dosing
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
*non-FDA-approved indication
Acarbose: (Moderate) Digestive enzyme preparations containing carbohydrate-splitting enzymes may reduce the pharmacologic effect of alpha-glucosidase inhibitors and should not be administered concurrently. Separating the timing of administration should limit an interaction, but is not usually feasible given the usual timing of administration around meals for both drugs.
Alpha-glucosidase Inhibitors: (Moderate) Digestive enzyme preparations containing carbohydrate-splitting enzymes may reduce the pharmacologic effect of alpha-glucosidase inhibitors and should not be administered concurrently. Separating the timing of administration should limit an interaction, but is not usually feasible given the usual timing of administration around meals for both drugs.
Aluminum Hydroxide: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Aluminum Hydroxide; Magnesium Carbonate: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Aluminum Hydroxide; Magnesium Hydroxide: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Aluminum Hydroxide; Magnesium Trisilicate: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Antacids: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Aspirin, ASA; Citric Acid; Sodium Bicarbonate: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Calcium Carbonate: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Calcium Carbonate; Famotidine; Magnesium Hydroxide: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Calcium Carbonate; Magnesium Hydroxide: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Calcium Carbonate; Magnesium Hydroxide; Simethicone: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Calcium Carbonate; Simethicone: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Calcium; Vitamin D: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Magnesium Hydroxide: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Miglitol: (Moderate) Digestive enzyme preparations containing carbohydrate-splitting enzymes may reduce the pharmacologic effect of alpha-glucosidase inhibitors and should not be administered concurrently. Separating the timing of administration should limit an interaction, but is not usually feasible given the usual timing of administration around meals for both drugs.
Omeprazole; Sodium Bicarbonate: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Sodium Bicarbonate: (Major) The effectiveness of gastrointestinal enzymes can be diminished with concurrent administration of antacids. In-vitro studies suggest that calcium and magnesum cations exert their deleterious effect on replacement enzyme therapy by formation of poorly soluble calcium or magnesium soaps and precipitation of glycine conjugated bile salts.
Following activation in the alkaline pH of the duodenum, pancrelipase releases high levels of lipase, amylase, and protease, which facilitate the hydrolysis of fats into glycerol and fatty acids, starches into dextrins and sugars, and proteins into peptides. Factors that influence the effectiveness of pancrelipase are those that affect the quantity of enzymatic activity reaching the small intestine, such as dose, gastrointestinal pH, and the microsphere size of the product.
Pancrelipase is administered orally; pancrelipase products are not interchangeable due to differences in pancreatic enzyme contents and release mechanisms. Pancrelipase is excreted in the feces.
-Route-Specific Pharmacokinetics
Oral Route
Pancrelipase is not absorbed following oral administration but exerts its action locally in the GI tract. Enzymatic activity of pancrelipase formulations can show considerable individual variation dependent on gastric pH. Some pancrelipase preparations contain enteric-coated microspheres of pancreatic enzyme, which inhibit gastric inactivation during gastric passage and deliver more of the enzymes to the duodenum where they are active.
-Special Populations
Pediatrics
The pharmacokinetics of pancrelipase in pediatric populations do not appear to differ from the pharmacokinetic parameters of young adults.
Elderly
The pharmacokinetics of pancrelipase in elderly populations do not appear to differ from the pharmacokinetic parameters of young adults.